Literature DB >> 16023214

Prevalence of myopia at 9 months in infants with high-risk prethreshold retinopathy of prematurity.

Bradley V Davitt1, Velma Dobson, William V Good, Robert J Hardy, Graham E Quinn, R Michael Siatkowski, C Gail Summers, Betty Tung.   

Abstract

PURPOSE: To examine the prevalence of myopia and high myopia at 9 months corrected age in premature infants who participated in the multicenter randomized trial of Early Treatment for Retinopathy of Prematurity (ETROP).
DESIGN: Randomized, controlled clinical trial. PARTICIPANTS: Four hundred one infants with birth weights of <1251 g in whom prethreshold ROP developed in one or both eyes and who were determined to have a significant risk (> or =15%) of poor structural outcomes without treatment, based on the risk management for ROP program. INTERVENTION: Infants with bilateral high-risk prethreshold ROP (n = 317) had 1 eye randomized to early treatment, and the fellow eye was managed conventionally. In asymmetric cases (n = 84), the eye with high-risk prethreshold ROP was randomized to early treatment or conventional management (control). Eyes randomized to early treatment at high-risk prethreshold ROP and eyes randomized to conventional management in which threshold ROP developed received peripheral retinal photocoagulation or cryotherapy. Conventionally managed eyes in which threshold ROP did not develop were observed. Cycloplegic retinoscopy data were obtained at 9 months corrected age from 321 eyes treated early and 307 eyes managed conventionally. MAIN OUTCOME MEASURES: Prevalence of myopic (spherical equivalent > or = 0.25 diopters [D]) and highly myopic (> or =5.00 D) eyes in each group.
RESULTS: The prevalence of myopia (64.5% vs. 69.4%; P = 0.06) and high myopia (25.5% vs. 28.3%; P = 0.20) was similar between eyes treated at high-risk prethreshold and high-risk prethreshold eyes managed conventionally. Among high-risk eyes managed conventionally, the prevalence of myopia (78.2% vs. 53.3%) and high myopia (37.6% vs. 11.2%) was higher when threshold ROP developed than when regression without treatment occurred. Among eyes treated at high-risk prethreshold ROP, the prevalence of myopia (93.3% vs. 91.7% vs. 60.6%) and of high myopia (53.3% vs. 33.3% vs. 20.8%) was higher in eyes with abnormal angle of temporal retinal vessels or macular ectopia than in eyes with no retinal residua. This also held true for conventionally managed eyes.
CONCLUSIONS: Early treatment at high-risk prethreshold did not place eyes at greater risk of myopia and high myopia than did conventional management of eyes with high-risk prethreshold ROP.

Entities:  

Mesh:

Year:  2005        PMID: 16023214     DOI: 10.1016/j.ophtha.2005.03.025

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  22 in total

Review 1.  The neurovascular retina in retinopathy of prematurity.

Authors:  Anne B Fulton; Ronald M Hansen; Anne Moskowitz; James D Akula
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

2.  Long-term evaluation of refractive changes in eyes of preterm children: a 6-year follow-up study.

Authors:  Mahmut Kaya; Ayse Tulin Berk; Aylin Yaman
Journal:  Int Ophthalmol       Date:  2017-07-01       Impact factor: 2.031

3.  Visual outcome and refractive status in first 3 years of age in preterm infants suffered from laser-treated Type 1 retinopathy of prematurity (ROP): a 6-year retrospective review in a tertiary centre in Hong Kong.

Authors:  Julie Y C Lok; Wilson W K Yip; Abbie S W Luk; Joyce K Y Chin; Henry H W Lau; Alvin L Young
Journal:  Int Ophthalmol       Date:  2017-01-04       Impact factor: 2.031

4.  Progression of myopia and high myopia in the Early Treatment for Retinopathy of Prematurity study: findings at 4 to 6 years of age.

Authors:  Graham E Quinn; Velma Dobson; Bradley V Davitt; David K Wallace; Robert J Hardy; Betty Tung; Dejian Lai; William V Good
Journal:  J AAPOS       Date:  2013-04       Impact factor: 1.220

5.  Prevalence and course of strabismus through age 6 years in participants of the Early Treatment for Retinopathy of Prematurity randomized trial.

Authors:  Deborah K VanderVeen; Don L Bremer; Rae R Fellows; Robert J Hardy; Daniel E Neely; Earl A Palmer; David L Rogers; Betty Tung; William V Good
Journal:  J AAPOS       Date:  2011-12       Impact factor: 1.220

6.  Astigmatism progression in the early treatment for retinopathy of prematurity study to 6 years of age.

Authors:  Bradley V Davitt; Graham E Quinn; David K Wallace; Velma Dobson; Robert J Hardy; Betty Tung; Dejian Lai; William V Good
Journal:  Ophthalmology       Date:  2011-08-27       Impact factor: 12.079

7.  Ophthalmic short- and long-term outcomes for premature infants: Results of an extended follow-up program in Saudi Arabia.

Authors:  Afaf A Bin-Khathlan; Fatin N Al-Ballaa; Abdullah K AlYahya
Journal:  Saudi J Ophthalmol       Date:  2014-05-24

8.  Astigmatism in the Early Treatment for Retinopathy Of Prematurity Study: findings to 3 years of age.

Authors:  Bradley V Davitt; Velma Dobson; Graham E Quinn; Robert J Hardy; Betty Tung; William V Good
Journal:  Ophthalmology       Date:  2008-12-16       Impact factor: 12.079

Review 9.  Screening and Treatment in Retinopathy of Prematurity.

Authors:  Andreas Stahl; Wolfgang Göpel
Journal:  Dtsch Arztebl Int       Date:  2015-10-23       Impact factor: 5.594

10.  Retinopathy of prematurity in the United Kingdom: retreatment rates, visual and structural 1-year outcomes.

Authors:  Gillian Gw Adams; Catey Bunce; Wen Xing; Lucilla Butler; Vernon Long; Aravind Reddy; Annegret H Dahlmann-Noor
Journal:  Eye (Lond)       Date:  2018-07-16       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.